JP2021522802A5 - - Google Patents

Info

Publication number
JP2021522802A5
JP2021522802A5 JP2020561923A JP2020561923A JP2021522802A5 JP 2021522802 A5 JP2021522802 A5 JP 2021522802A5 JP 2020561923 A JP2020561923 A JP 2020561923A JP 2020561923 A JP2020561923 A JP 2020561923A JP 2021522802 A5 JP2021522802 A5 JP 2021522802A5
Authority
JP
Japan
Prior art keywords
composition according
treatment period
compound
hcv
days
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020561923A
Other languages
English (en)
Japanese (ja)
Other versions
JP7279081B2 (ja
JP2021522802A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/031044 external-priority patent/WO2019217369A1/en
Publication of JP2021522802A publication Critical patent/JP2021522802A/ja
Publication of JP2021522802A5 publication Critical patent/JP2021522802A5/ja
Application granted granted Critical
Publication of JP7279081B2 publication Critical patent/JP7279081B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020561923A 2018-05-08 2019-05-07 Ｍｉｒ－１２２を調節するためのマイクロｒｎａ化合物及び方法 Active JP7279081B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862668467P 2018-05-08 2018-05-08
US62/668,467 2018-05-08
PCT/US2019/031044 WO2019217369A1 (en) 2018-05-08 2019-05-07 Galnac conjugated modified oligonucleotide as mir-122 inhibitor having hcv antiviral activity with reduced hyperbilirubinemia side-effect

Publications (3)

Publication Number Publication Date
JP2021522802A JP2021522802A (ja) 2021-09-02
JP2021522802A5 true JP2021522802A5 (enExample) 2022-05-13
JP7279081B2 JP7279081B2 (ja) 2023-05-22

Family

ID=66625315

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020561923A Active JP7279081B2 (ja) 2018-05-08 2019-05-07 Ｍｉｒ－１２２を調節するためのマイクロｒｎａ化合物及び方法

Country Status (7)

Country Link
US (1) US12005120B2 (enExample)
EP (1) EP3790972A1 (enExample)
JP (1) JP7279081B2 (enExample)
CN (1) CN112400020B (enExample)
CA (1) CA3099698A1 (enExample)
TW (1) TWI854980B (enExample)
WO (1) WO2019217369A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113718024A (zh) * 2020-05-26 2021-11-30 深圳市血液中心 血浆miRNA标志物及其应用
AU2023238507A1 (en) * 2022-03-25 2024-10-31 Hansoh Bio Llc Bicyclic heterocycles and their ligands for targeted delivery of therapeutic agents

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995030746A1 (en) 1994-05-10 1995-11-16 The General Hospital Corporation Antisense inhibition of hepatitis c virus
CN1120707C (zh) 1995-11-22 2003-09-10 约翰斯·霍普金斯大学 增强生物分子的细胞摄取的配体
US6300319B1 (en) 1998-06-16 2001-10-09 Isis Pharmaceuticals, Inc. Targeted oligonucleotide conjugates
US6656730B1 (en) 1999-06-15 2003-12-02 Isis Pharmaceuticals, Inc. Oligonucleotides conjugated to protein-binding drugs
AU7406700A (en) 1999-10-04 2001-05-10 Exiqon A/S Design of high affinity rnase h recruiting oligonucleotide
IL149694A0 (en) 1999-12-23 2002-11-10 Exiqon As Therapeutic uses of lna-modified oligonucleotides
US7491805B2 (en) 2001-05-18 2009-02-17 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
CN100406065C (zh) 2000-12-01 2008-07-30 细胞工厂治疗公司 糖基化/半乳糖基化肽、双官能接头和核苷酸单体/多聚体的缀合物以及相关的组合物和使用方法
CN1344803A (zh) 2001-09-27 2002-04-17 吴昌 核酸靶分子选择及扩增方法
ES2702942T3 (es) 2003-04-17 2019-03-06 Alnylam Pharmaceuticals Inc Agentes de ARNi modificados
US8969314B2 (en) 2003-07-31 2015-03-03 Regulus Therapeutics, Inc. Methods for use in modulating miR-122a
US7683036B2 (en) 2003-07-31 2010-03-23 Regulus Therapeutics Inc. Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
AU2004275876B2 (en) 2003-09-25 2011-03-31 Coley Pharmaceutical Gmbh Nucleic acid-lipophilic conjugates
WO2005061710A1 (en) 2003-12-23 2005-07-07 Santaris Pharma A/S Oligomeric compounds for the modulation of bcl-2
EP1768998A2 (en) 2004-04-27 2007-04-04 Alnylam Pharmaceuticals Inc. Single-stranded and double-stranded oligonucleotides comprising a 2-arylpropyl moiety
ES2361458T5 (es) 2004-05-04 2016-04-20 The Board Of Trustees Of The Leland Stanford Junior University Procedimientos y composiciones para reducir las cantidades de genoma vírico de VHC en una célula diana
AU2005330637B2 (en) 2004-08-04 2012-09-20 Alnylam Pharmaceuticals, Inc. Oligonucleotides comprising a ligand tethered to a modified or non-natural nucleobase
US20090203132A1 (en) 2004-09-09 2009-08-13 Swayze Eric E Pyrrolidinyl groups for attaching conjugates to oligomeric compounds
EP1838870A2 (en) 2004-12-29 2007-10-03 Exiqon A/S NOVEL OLIGONUCLEOTIDE COMPOSITIONS AND PROBE SEQUENCES USEFUL FOR DETECTION AND ANALYSIS OF MICRORNAS AND THEIR TARGET MRNAs
US20120122801A1 (en) 2005-01-05 2012-05-17 Prosensa B.V. Mannose-6-phosphate receptor mediated gene transfer into muscle cells
US20060148740A1 (en) 2005-01-05 2006-07-06 Prosensa B.V. Mannose-6-phosphate receptor mediated gene transfer into muscle cells
US20080206869A1 (en) 2005-01-24 2008-08-28 Avaris Ab Nucleic Acid Complex
AU2006279906B2 (en) 2005-08-10 2012-05-10 Alnylam Pharmaceuticals, Inc. Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof
US20070213292A1 (en) 2005-08-10 2007-09-13 The Rockefeller University Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof
EP1931780B1 (en) 2005-08-29 2016-01-06 Regulus Therapeutics Inc. Antisense compounds having enhanced anti-microrna activity
AU2007211082B2 (en) 2006-01-27 2012-09-27 Isis Pharmaceuticals, Inc. Oligomeric compounds and compositions for the use in modulation of microRNAs
EP2007888A2 (en) 2006-04-03 2008-12-31 Santaris Pharma A/S Pharmaceutical composition comprising anti-mirna antisense oligonucleotides
SG10201406016SA (en) 2006-04-03 2014-11-27 Stella Aps Pharmaceutical composition comprising anti-mirna antisense oligonucleotides
DK2152879T3 (da) 2007-05-01 2013-02-18 Santaris Pharma As RNA antagonistforbindelser til modulering af beta-catenin
EP2623599B1 (en) 2007-10-04 2019-01-02 Roche Innovation Center Copenhagen A/S Micromirs
WO2009068033A2 (en) 2007-11-26 2009-06-04 Santaris Pharma A/S Lna antagonists targeting the androgen receptor
WO2009073809A2 (en) 2007-12-04 2009-06-11 Alnylam Pharmaceuticals, Inc. Carbohydrate conjugates as delivery agents for oligonucleotides
WO2009091972A2 (en) 2008-01-18 2009-07-23 Alnylam Pharmaceuticals, Inc. Chemically modified oligonucleotides and small molecules for use in reducing micro rna activity levels and uses thereof
CA2717792A1 (en) 2008-03-07 2009-09-11 Santaris Pharma A/S Pharmaceutical compositions for treatment of microrna related diseases
WO2010076248A1 (en) 2008-12-31 2010-07-08 Santaris Pharma A/S Use of lna apob antisense oligomers for the treatment of acute coronary syndromes
ES2599979T3 (es) 2009-04-24 2017-02-06 Roche Innovation Center Copenhagen A/S Composiciones farmacéuticas para el tratamiento de pacientes de VHC que no responden al interferón
SG176716A1 (en) 2009-06-08 2012-01-30 Miragen Therapeutics CHEMICAL MODIFICATION MOTIFS FOR miRNA INHIBITORS AND MIMETICS
BR112012008865A2 (pt) 2009-10-16 2019-09-24 Glaxo Group Ltd inibidores de hbv anti-sentido.
SI2539451T1 (sl) 2010-02-24 2016-04-29 Arrowhead Research Corporation Sestavki za ciljano dostavo sirna
EP2553019A1 (en) 2010-03-26 2013-02-06 Mersana Therapeutics, Inc. Modified polymers for delivery of polynucleotides, method of manufacture, and methods of use thereof
WO2011130458A2 (en) 2010-04-13 2011-10-20 John Rossi Rna aptamers against baff-r as cell-type specific delivery agents and methods for their use
WO2012007477A1 (en) 2010-07-12 2012-01-19 Santaris Pharma A/S Anti hcv oligomers
CA2812046A1 (en) 2010-09-15 2012-03-22 Alnylam Pharmaceuticals, Inc. Modified irna agents
AU2011343664B2 (en) 2010-12-17 2015-10-08 Arrowhead Pharmaceuticals, Inc. Galactose cluster-pharmacokinetic modulator targeting moiety for siRNA
CA3131967A1 (en) 2010-12-29 2012-07-05 F. Hoffman-La Roche Ag Small molecule conjugates for intracellular delivery of nucleic acids
HUE031595T2 (en) 2011-04-25 2017-07-28 Regulus Therapeutics Inc Micro RNA Compounds s Methods for Modulating Mir-21 Activity
EP2722388B1 (en) 2011-06-16 2017-08-09 Nippon Steel & Sumikin Eco-Tech Corporation Nucleic acid probe for assaying nucleic acids
WO2012175733A1 (en) 2011-06-23 2012-12-27 Santaris Pharma A/S Hcv combination therapy
WO2013000856A1 (en) 2011-06-30 2013-01-03 Santaris Pharma A/S Hcv combination therapy
JP2014520772A (ja) 2011-06-30 2014-08-25 ステラ・アンパルトセルスカブ Ｈｃｖ併用療法
WO2013033230A1 (en) 2011-08-29 2013-03-07 Isis Pharmaceuticals, Inc. Oligomer-conjugate complexes and their use
WO2013068348A1 (en) 2011-11-07 2013-05-16 Santaris Pharma A/S Lna oligomers for improvement in hepatic function
AU2012334214A1 (en) 2011-11-07 2014-05-22 Roche Innovation Center Copenhagen A/S Prognostic method for checking efficacy of micro RNA-122 inhibitors in HCV+ patients
CN107236735B (zh) 2012-06-21 2019-11-08 米拉根医疗股份有限公司 包含锁核酸基序的基于寡核苷酸的抑制剂
AU2013324716B2 (en) 2012-09-26 2019-06-13 Guandong Mijinjia Biotechnology Co., Ltd Oligomers with improved off-target profile
CN104837996A (zh) 2012-11-15 2015-08-12 罗氏创新中心哥本哈根有限公司 抗apob反义缀合物化合物
WO2014118272A1 (en) * 2013-01-30 2014-08-07 Santaris Pharma A/S Antimir-122 oligonucleotide carbohydrate conjugates
AU2014211406B2 (en) 2013-01-30 2019-07-18 Roche Innovation Center Copenhagen A/S LNA oligonucleotide carbohydrate conjugates
US9506030B2 (en) 2013-05-01 2016-11-29 Regulus Therapeutics Inc. Compounds and methods for enhanced cellular uptake
SG10201803157XA (en) 2013-05-01 2018-05-30 Regulus Therapeutics Inc Microrna compounds and methods for modulating mir-122
DK2992098T3 (da) 2013-05-01 2019-06-17 Ionis Pharmaceuticals Inc Sammensætninger og fremgangsmåder til modulering af hbv- og ttr-ekspression

Similar Documents

Publication Publication Date Title
Gentile et al. A novel promising therapeutic option against hepatitis C virus: an oral nucleotide NS5B polymerase inhibitor sofosbuvir
JP2008518943A5 (enExample)
JP2010503396A5 (enExample)
JP2021521118A5 (enExample)
AR079555A1 (es) Metodos de tratamiento de la infeccion de virus de hepatitis b (hbv) y virus de hepatitis c (hcv)
Bourlière et al. Sofosbuvir as backbone of interferon free treatments
CN108712905B (zh) 抗肝肿瘤病毒剂
WO2010031832A9 (en) Synergistic combinations of a macrocyclic inhibitor of hcv and a thiophene-2-carboxylic acid derivative
TW200815384A (en) Combination therapy method for treating hepatitis C virus infection and pharmaceutical compositions for use therein
KR20120139699A (ko) Ｃ형 간염 바이러스 감염의 치료 요법
JP2013540112A (ja) Ｈｃｖ感染を治療するための併用療法
JP2011522862A (ja) テラプレビル（Ｔｅｌａｐｒｅｖｉｒ）投薬養生法
JP2021522802A5 (enExample)
Schinazi et al. Sofosbuvir (sovaldi): The first‐in‐class HCV ns5b nucleotide polymerase inhibitor
US10471048B2 (en) Thienopyridine derivative for the treatment of hepatitis C infections
US20130028865A1 (en) Combination of a Macrocyclic Inhibitor of HCV, A Non-Nucleoside and a Nucleoside
WO2014033668A2 (en) Combination of a macrocyclic protease inhibitor of hcv, a non-nucleoside hcv inhibitor and ritonavir
JP2021523129A5 (enExample)
Garg et al. Management of HCV infection: current issues and future options
Amblard et al. Nucleoside Antiviral Agents for HCV: what's Left to Do?
Reviriego Daclatasvir dihydrochloride
US10201541B1 (en) Compositions and methods for treating HCV
US20130273003A1 (en) Therapies for Treating Hepatitis C Virus Infection
JP2017514834A (ja) Ｈｃｖ感染症を治療するための組合せ療法
Kaur et al. Emerging therapies in pipeline for chronic hepatitis C